CT/NG検査市場は、2023年の17億ドル、2028年までに27億ドルに成長すると予想され、予測期間中のCAGRは8.6%と推定されます。この市場で活動している主なプレーヤーは、F. Hoffmann-La Roche Ltd. (スイス)、Hologic, Inc. (米国)、Thermo Fisher Scientific Inc. (米国)、Abbott Laboratories (米国)、QIAGEN (オランダ)、PerkinElmer Inc です。 . (米国)、Bio-Rad Laboratories, Inc. (米国)、Siemens Healthineers AG (ドイツ)、Danaher (米国)、Becton, Dickinson and Company (米国)、Seegene, Inc. (韓国)、Meridian Bioscience Inc. (米国)、Binx Health, Inc. (米国)、Visby Medical, Inc. (米国)、Geneproof AS (チェコ共和国)、Bioneer Corporation (韓国)、Genetic Signatures (オーストラリア)、Microbiologics, Inc. (米国)、 Vircell SL (スペイン)、Sansure Biotech Inc. (中
目次
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.4 YEARS CONSIDERED FOR THE STUDY
1.5 CURRENCY
1.6 LIMITATIONS
1.7 STAKEHOLDERS
1.8 SUMMARY OF CHANGES
1.8.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 SECONDARY DATA
2.2.1 KEY DATA FROM SECONDARY SOURCES
2.3 PRIMARY DATA
2.3.1 KEY DATA FROM PRIMARY SOURCES
2.4 MARKET SIZE ESTIMATION
2.4.1 BOTTOM-UP APPROACH
2.4.2 GROWTH FORECAST
2.4.3 TOP-DOWN APPROACH
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6 MARKET SHARE ANALYSIS
2.7 STUDY ASSUMPTIONS
2.8 RISK ASSESSMENT
2.9 LIMITATIONS
2.10 RECESSION IMPACT: CT/NG TESTING MARKET
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 PRICING ANALYSIS
5.4 VALUE CHAIN ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 PORTER’S FIVE FORCES ANALYSIS
5.8 REGULATORY LANDSCAPE
5.9 PESTLE ANALYSIS
5.10 TRADE ANALYSIS
5.11 PATENT ANALYSIS
6 GLOBAL CT/NG DIAGNOSTICS MARKET, BY PRODUCT (USD MILLION)
6.1 INTRODUCTION
6.2 ASSAYS AND KITS
6.3 INSTRUMENTS/ANALYZERS
7 GLOBAL CT/NG DIAGNOSTICS MARKET, BY TESTING TYPE (VALUE IN USD MILLIONS AND VOLUME IN MILLION TESTS)
7.1 INTRODUCTION
7.2 POINTOF CARE TESTING
7.3 LABORATORY TESTING
8 GLOBAL CT/NG DIAGNOSTICS MARKET, BY TECHNOLOGY
8.1 INTRODUCTION
8.3 INAAT
8.4 PCR
8.5 IMMUNODIAGNOSTICS
8.6 OTHER TECHNOLOGIES
9 GLOBAL CT/NG DIAGNOSTICS MARKET, BY END USER
9.1 INTRODUCTION
9.2 DIAGNOSTIC LABORATORIES
9.3 HOSPITALS AND CLINICS
9.4 OTHER END USERS
10 GLOBAL CT/NG DIAGNOSTICS MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 UK
10.3.3 FRANCE
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 CHINA
10.4.2 JAPAN
10.4.3 INDIA
10.4.4 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
11 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.3 REVENUE SHARE ANALYSIS
10.4 MARKET SHARE ANALYSIS
10.5 COMPANY EVALUATION QUADRANT
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.6 COMPANY EVALUATION QUADRANT FOR SMES/START-UPS
10.6.1 PROGRESSIVE COMPANIES
10.6.2 STARTING BLOCKS
10.6.3 RESPONSIVE COMPANIES
10.6.4 DYNAMIC COMPANIES
10.7 COMPANY FOOTPRINT ANALYSIS
10.7.1 COMPANY FOOTPRINT
10.7.2 COMPANY REGIONAL FOOTPRINT
10.7.3 COMPANY PRODUCT FOOTPRINT
10.8 COMPETITIVE SCENARIO
10.8.1 PRODUCT LAUNCHES
10.8.2 DEALS
10.8.3 EXPANSIONS
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products and Services Offered, Recent Developments, MnM View, Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats)*
12.1.1 HOLOGIC INC.
12.1.2 DANAHER CORPORATION
12.1.3 F. HOFFMAN LA ROCHE LTD.
12.1.4 ABBOTT LABORATORIES
12.1.5 BECTON DICKINSON AND CO.
12.1.6 CEPHEID
12.1.7 QIAGEN
12.1.8 BAYER HEALTHCARE
12.1.9 DAKO
12.1.10 SIEMENS
12.1.11 SYSMEX
12.1.12 GRIFOLS
12.1.13 BIOMERIEUX
*Details on Business Overview, Products and Services Offered, Recent Developments, MnM View, Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats might not be captured in case of unlisted companies.
13 APPENDIX
13.1 INDUSTRY INSIGHTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
